Athenex Inc

0.00 (-1.43%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)43.21M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$28.92 Million
Adjusted EPS-$0.15
See more estimates
10-Day MA$0.29
50-Day MA$0.49
200-Day MA$0.72
See more pivots

Athenex Inc Stock, NASDAQ:ATNX

Conventus Building, 1001 Main Street, Buffalo, New York 14203-1009
United States of America
Phone: +1.716.427.2950
Number of Employees: 666


Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. It operates through the following segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Global Supply Chain Platform segment provides supply of active pharmaceutical ingredients for clinical and commercial efforts. The Commercial Platform segment involves the sale and marketing of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.